The General Hospital Corporation

Memorial Sloan Kettering Cancer Center

Thomas Reiner

Ralph Weissleder

Jason S Lewis

Zahi A Fayad

Edmund J Keliher

Wolfgang Weber

Brian Zeglis

Giuseppe Carlucci

Beatriz Salinas Rodriguez

Jacob Lee Houghton

Brandon Carney

Jan-Philip Meyer

Christian Brand

Carlos Perez-medina

Willem JM Mulder

Edward Fisher

Described herein are Tz/TCO-based pretargeting strategies using an Al[F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-basedF imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life,F is more readily available to produce and therefore integrated into hospital workflows.

Radioligands for pretargeted pet imaging and methods of their therapeutic use

This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.

Compositions and methods for in vivo imaging

Disclosed are chemical entities of formula (I) wherein R, Rand n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed. 

Radiohalide-labeled targeted diagnostics and therapeutics

The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.

Imaging beta cell mass

Growing community of inventors

Weehawken, NJ, United States of America

Thomas Reiner